Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Salus Alpha’s strategies start 2014 with strong performances

Tuesday, February 18, 2014

Komfie Manalo, Opalesque Asia:

Salus Alpha’s strategies started 2014 on a positive note with strong performances, according to the DB select Manager Performance Flash Report – January 2014, produced by independent Managed Investment Platform db Select.

The strategies delivered positive returns during the month of January, led by the Salus Alpha Directional Markets Strateg (ranked 3rd out of 69 listed CTA programs on DB Select Platform) which was up +5.75% and outperforming the world biggest CTA power houses by a positive margin of 6.5% on average during the month. Further, the Salus Alpha Global Alpha Strategy (ranked 8th out of 69 listed CTA programmes on DB Select Platform) was up by +2.08% in January.

Both programs enjoyed also positive performance in 2013 contrary to most CTAs. Our programmes were able to take advantage of volatility which is back in the markets due to volatile fundamental data led by weak U.S. jobs and discouraging PMI numbers from China.

Market sentiment weakened further towards the end of the month, as the Federal Reserve announced another round of tapering which raised concerns regarding the health of the global recovery.

Oliver Prock, CEO and CIO of Salus Alpha Capital said, "Our strategies seem to repeat the January stint in February and in the coming months because our approach is unique and able to generate positive returns in all environ......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its